Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.

The British journal of dermatology - 1 Aug 2012

Lamprecht B, Kreher S, Möbs M, Sterry W, Dörken B, Janz M, Assaf C, Mathas S

Abstract excerpt

BACKGROUND: Primary cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group with Sézary syndrome (SS) as one of the most aggressive variants. Recently, we identified a loss of E2A as a recurrent event in SS, which enhanced proliferation via upregulation of the proto-oncogene MYC. MYC-induced transformation usually requires deleterious alterations of key apoptotic genes including p53; however, p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to Immunoblotting
Share to Loss of Heterozygosity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-mdm2

Share to Sequence Analysis, RNA

Share to Skin Neoplasms

Source

Identifiers

PMID: 22384858
DOI: 10.1111/j.1365-2133.2012.10918.x

Genes

MYC
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.PMID 22384858Read ↗

TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.Semantic proximity Read ↗

Sézary syndrome: old enigmas, new targets.Semantic proximity Read ↗

MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndromeSemantic proximity Read ↗

Diverse transcriptomic and mutational patterns but limited functional pathway alterations in patient-derived Sézary syndrome cells.Semantic proximity Read ↗

Sézary Syndrome: Translating Genetic Diversity into Personalized Medicine.Semantic proximity Read ↗

Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndromeSemantic proximity Read ↗

NOTCH1 signaling as a therapeutic target in Sézary syndrome.Semantic proximity Read ↗

Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.Semantic proximity Read ↗

New Insights Into the Complex Mutational Landscape of Sézary SyndromeSemantic proximity Read ↗

The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.Semantic proximity Read ↗

Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndromeSemantic proximity Read ↗

Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.